Zum Inhalt

The Impact of Age on the Post-operative Outcomes in Patients Undergoing Resection for Oesophageal and Gastric Cancer

  • Open Access
  • 18.10.2023
  • Original Scientific Report
Erschienen in:

Abstract

Background

Within our ageing population, there is an increasing number of elderly patients presenting with oesophagogastric cancer. Resection remains the mainstay of curative treatment however it has substantial morbidity. The aim of this study was to assess whether age was an independent predictor of resection related complications in our unit.

Methods

A retrospective cohort study of prospectively collated data from 2002 to 2020 of patients undergoing resection for oesophageal and gastric cancers was analysed. Patients aged over 75 and 75 and under were compared for peri-operative morbidity (via the Clavien-Dindo classification), length of stay (LOS), unplanned readmission, 30- and 90-day mortality, and use of neoadjuvant therapy.

Results

Data for 466 consecutive patients undergoing oesophagogastric resection (277 oesophagectomy and 189 gastrectomy) were available for analysis. 22% of patients were aged over 75 (14% (39/277) of the oesophagectomy cohort, 34% (65/189) of the gastrectomy cohort). Oesophagectomy patients over 75 were more likely to develop post-operative complications, particularly cardiac or thromboembolic, (69.2%) than those in the younger cohort (50.4%, p = 0.029). There was no difference in complication rates between the younger and older patients undergoing gastrectomy (29.0% vs. 33.9% p = 0.495). The 30- and 90-day mortality rates were 1.4% (n = 4) and 2.5% (n = 7), respectively, for the oesophagectomy cohort and 1.1% (n = 2) and 1.6% (n = 3) for the gastrectomy cohort, with no difference between age groups.

Conclusion

In this series, we found that patients over the age of 75 were able to undergo oesophageal and gastric resection with curative intent with acceptable post-operative morbidity and mortality.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

As the life expectancy of our population increases, there is a greater incidence of oesophagogastric cancer, particularly in the elderly population [1, 2]. Treatment is complex and resource intensive and usually includes adjuvant therapy combined with complex foregut resection [35].
Foregut resection in the elderly is generally undertaken with caution due to increased frailty, greater comorbidities and impaired nutritional status. While it would be reasonable to assume that older patients undergoing oesophagogastric resection would have higher rates of perioperative complication [6, 7], the available evidence is limited and conflicting. Some retrospective studies support the idea that elderly patients suffer more post-operative medical complications [8], and subsequently higher rates of mortality [9], though opposing evidence indicates comparable morbidity and mortality rates [10, 11]. Available data are further confounded by the use of adjuvant therapies which may result in higher complication rates in the elderly and therefore are frequently omitted [1214].
The aim of this study was to ascertain whether increased age, over 75 years, has an adverse effect on post-operative, short-term, outcomes in patients undergoing oesophagogastric resection.

Materials and methods

A single unit cohort study of patients undergoing curative resection for oesophagogastric cancer between 2002 and 2020 at two co-located hospitals was undertaken (Royal North Shore and North Shore Private hospitals). Ethics approval was given by the Human Research Ethics Committee of the New South Wales Northern Sydney Local Health District, HREC reference number 2022/ETH00802. Patients with oesophagogastric cancer who underwent curative surgical resection in our unit were retrospectively identified from a prospectively collated database. Patients undergoing resection for benign disease or where concurrent laryngeal resection was performed were excluded from the study.
The database included patient characteristics (age, sex, smoking status), the American Society of Anesthesiologists (ASA) grade of the patient [15], comorbidities, operative details, use of adjuvant therapy, type and stage of disease. Post-operative data included length of stay (LOS), unplanned return to theatre, unplanned ICU admission, unplanned reintubation, unplanned readmission to hospital, in-hospital mortality, and 30- and 90-day mortality. Specific surgical complications recorded included anastomotic leak, haemorrhage, intra-abdominal abscess, wound infection and chylothorax. Non-surgical complications included respiratory, cardiac and thrombo-embolic. Collected data were examined with a focus on age greater than 75 years, and 75 years or younger.
Treatment and perioperative data collected early in this series were based on the data set from the Association of Upper Gastrointestinal Surgeons of the United Kingdom and Ireland (AUGIS), and severity of complications was recorded using the Clavien-Dindo grading system [16]. Later in the series, details of complications were recorded according to the International Oesophagectomy Complications Consensus Group [17].
Pre-treatment staging comprised of CT and FDG PET scans. Staging laparoscopy was performed for those patients with gastric or junctional cancer. Patients were routinely discussed at a multidisciplinary team meeting. Patients with a gastric malignancy, or a Siewart type 3 oesophagogastric junctional cancer, underwent a total or subtotal gastrectomy. Oesophageal resection in this series was either via open Ivor Lewis resection or hybrid thoracoscopic 3 stage resection dependent on tumour location. Thoracic epidural and on table extubation were routine. Surgery was performed by the two senior authors (SL and GS) or trainees under their supervision.
Categorical variables were presented as counts and percentages and analysed using Fishers’ exact or Chi-square tests. Continuous variables were expressed as mean and standard deviation for normally distributed data and analysed using T tests. Continuous variables which were not normally distributed were expressed as median and range and analysed using Mann–Whitney U test. Association of variables with complications following oesophagectomy were assessed using logistic regression. All univariable analyses with p value < 0.2 were included in the multivariable model after testing for collinearity. Backward elimination was used as the variable selection method. The results were presented with an odds ratio (OR), 95% confidence interval (CI) and a corresponding p value.

Results

There were 466 consecutive patients included in this analysis of which 277 underwent oesophagectomy and 189 underwent gastrectomy. Of these patients, 22% were aged over 75 (n = 104); 14% of the oesophageal cohort (n = 39/277) and 34% of the gastric cohort (n = 65/189). Patient characteristics are outlined in Tables 1 and 2. Patients aged over 75, in both the oesophagectomy and gastrectomy cohorts, were more likely to be ASA grade 3 or higher (p = 0.002 and p = 0.005, respectively) and more frequently had pre-existing cardiovascular and neurological comorbidities. Tables 3 and 4 outline the treatment received, the histopathology and staging (TNM) of both oesophagectomy and gastrectomy patients. There were 103 patients with oesophageal cancer who underwent an Ivor Lewis resection, and 174 patients had a hybrid 3-stage resection (Table 3 37% vs. 63%). Amongst those with gastric cancer, 77 patients underwent a total gastrectomy, and 112 had either a subtotal (n = 104) or a distal gastrectomy (n = 8) (Table 4 41% vs. 59%).
Table 1
Oesophagectomy patient characteristics by age
 
Total population (n = 277)
Age ≤ 75 (n = 238)
Age > 75 (n = 39)
p value
Median Age (Range)
67(34–85)
   
Sex, n (%)
   
0.960
  Male
221(79.8)
190(79.8)
31(79.5)
 
  Female
56(20.2)
48(20.2)
8(20.5)
 
ASA Grade, n (%)
   
0.002
  1 or 2
157(56.7)
144(60.5)
13(33.3)
 
  3 or 4
120(43.3)
94(39.5)
26(66.7)
 
COPD, n (%)
33(11.9)
25(10.5)
8(20.5)
0.074
HTN, n (%)
78(28.2)
68(28.6)
10(25.6)
0.706
CAD, n (%)
41(14.8)
30(12.6)
11(28.2)
0.011
Arrhythmia, n (%)
28(10.1)
20(8.4)
8(20.5)
0.020
Diabetes, n (%)
33(11.9)
29(12.2)
4(10.3)
0.999
PE/DVT, n (%)
12(4.3)
10(4.2)
2(5.1)
0.679
TIA/CVA, n (%)
10(3.6)
5(2.1)
5(12.8)
0.001
Smoking, n (%)
20(7.2)
20(8.4)
0(0.0)
0.088
Renal, n (%)
6(2.2)
6(2.5)
0(0.0)
0.600
ASA American Society of Anesthesiologists; COPD Chronic Obstruction Pulmonary Disease; HTN Hypertension; CAD Coronary artery disease; PE Pulmonary embolism; DVT Deep venous thrombosis; TIA Transient ischaemic attack; CVA Cerebrovascular accident
Table 2
Gastrectomy patient characteristics by age
 
Total population (n = 189)
Age ≤ 75 (n = 124)
Age > 75 (n = 65)
p value
Median Age (Range)
71(30–91)
   
Sex, n (%)
   
0.088
  Male
112(59.3)
68(54.8)
44(67.7)
 
  Female
77(40.7)
56(45.2)
21(32.3)
 
ASA Grade, n (%)
   
0.005
  1 or 2
108(57.1)
80(64.5)
28(43.1)
 
  3 or 4
81(42.9)
44(35.5)
37(56.9)
 
COPD, n (%)
4(2.19)
2(1.6)
2(3.1)
0.609
HTN, n (%)
59(31.2)
31(25.0)
28(43.1)
0.011
CAD, n (%)
22(11.6)
10(8.1)
12(18.5)
0.034
Arrhythmia, n (%)
15(7.9)
6(4.8)
9(13.9)
0.030
Diabetes, n (%)
24(12.7)
13(10.5)
11(16.9)
0.207
PE/DVT, n (%)
9(4.8)
4(3.2)
5(7.7)
0.279
TIA/CVA, n (%)
6(3.2)
1(0.8)
5(7.7)
0.019
Smoking, n (%)
15(7.9)
12(9.7)
3(4.6)
0.269
Renal, n (%)
7(3.7)
3(2.4)
4(6.2)
0.235
ASA American Society of Anaesthesiologists; COPD Chronic Obstruction Pulmonary Disease; HTN Hypertension; CAD Coronary artery disease; PE Pulmonary embolism; DVT Deep venous thrombosis; TIA Transient ischaemic attack; CVA Cerebrovascular accident
Table 3
Oesophagectomy treatment and histopathological details by age
 
Total population (n = 277)
Age ≤ 75 (n = 238)
Age > 75 (n = 39)
p value
Neoadjuvant therapy, n (%)
   
0.753
  Chemo-radiotherapy
120(43.3)
103(43.3)
17(43.6)
 
  Chemotherapy
97(35.0)
85(35.7)
12(30.8)
 
  None
60(21.7)
50(21.0)
10(25.6)
 
Adjuvant chemotherapy, n (%)
43(15.5)
39(16.4)
4(10.3)
0.327
Hospital, n (%)
   
0.296
  Public
76(27.4)
68(28.6)
8(20.5)
 
  Private
201(72.6)
170(71.4)
31(79.5)
 
Procedure, n (%)
   
0.860
  Ivor Lewis
103(37.2)
88(37.0)
15(38.5)
 
  3 Stage
174(62.8)
150(63.0)
24(61.5)
 
Pathological T Stage, n (%)
   
0.34
  T0
28(10.1)
24(10.1)
4(10.3)
 
  T1
80(28.9
64(26.9
16(41.0
 
  T2
42(15.1)
36(15.1)
6(15.4)
 
  T3
114(41.2)
103(43.3)
11(28.2)
 
  T4
13(4.7)
11(4.6)
2(5.1)
0
Pathological N Stage, n (%)
   
0.96
  N0
157(56.7)
134(56.3)
23(59.0)
 
  N1
79(28.5)
69(29.0)
10(25.6)
 
  N2
25(9.0)
21(8.8)
4(10.3)
 
  N3
16(5.8)
14(5.9)
2(5.1)
0
Histopathology, n (%)
   
0.325
  Adenocarcinoma
227(82.0)
192(80.7)
35(89.7)
 
  Squamous cell carcinoma
43(15.5)
40(16.8)
3(7.7)
 
  Other
7(2.5)
6(2.5)
1(2.6)
 
Table 4
Gastrectomy treatment and histopathological details by age
 
Total population (n = 189)
Age ≤ 75 (n = 124)
Age > 75 (n = 65)
p value
Neoadjuvant chemotherapy, n (%)
71(37.6)
55(44.4)
16(24.6)
0.008
Adjuvant chemotherapy, n (%)
62(32.8)
55(44.4)
7(10.8)
 < 0.001
Hospital, n (%)
   
0.658
  Public
76(40.6)
51(41.8)
25(38.5)
 
  Private
111(59.4)
71(58.2)
40(61.5)
 
Gastrectomy, n (%)
   
0.163
  Distal or Subtotal
112(59.3)
69(55.7)
43(66.2)
 
  Total or Extended total
77(40.7)
55(44.3)
22(33.8)
 
Lymph node dissection, n (%)
   
0.145
  D1 or D1 + 
139(73.5)
87(70.2)
52(80.0)
 
  D2
50(26.5)
37(29.8)
13(20.0)
 
Pathological T Stage, n (%)
   
0.191
  T0
9(4.8)
7(5.6)
2(3.1)
 
  T1
55(29.1)
41(33.1)
14(21.5)
 
  T2
32(16.9)
16(12.9)
16(24.6)
 
  T3
62(32.8)
41(33.1)
21(32.3)
 
  T4
31(16.4)
19(15.3)
12(18.5)
 
Pathological N Stage, n (%)
   
0.196
  N0
96(50.8)
63(50.8)
33(50.8)
 
  N1
37(19.6)
22(17.8)
15(23.1)
 
  N2
24(12.7)
20(16.1)
4(6.1)
 
  N
32(16.9)
19(15.3)
13(20.0)
 
Histopathology, n (%)
   
0.301
  Adenocarcinoma
179(94.7)
115(92.8)
64(98.5)
 
  Neuroendocrine
3(1.6)
3(2.4)
0(0.0)
 
  Other
7(3.7)
6(4.8)
1(1.5)
 

Oesophagectomy cohort

Older patients undergoing oesophagectomy were as likely to receive adjuvant therapy as the younger cohort (Table 3). LOS in the older group was 17 days versus 15 days in the younger cohort although there was no statistical difference (p = 0.301).
There was no difference in mortality rates between the two cohorts; 30- and 90-day mortality rates in the older cohort were 2.6% and 2.6% (n = 1) and in the younger cohort 1.3% (n = 3) and 2.5% (n = 6), respectively (Table 5).
Table 5
Oesophagectomy outcomes by age
 
Total population (n = 277)
Age ≤ 75 (n = 238)
Age > 75 (n = 39)
p value
Overall post-op Complications, n (%)
147 (53.1)
120 (50.4)
27 (69.2)
0.029
Intra-op Complications, n (%)
6 (2.2)
5 (2.1)
1 (2.6)
0.999
Surgical Complications, n (%)
96 (34.7)
83 (34.9)
13 (33.3)
0.851
Non-Surgical Complications, n (%)
97 (35.0)
74 (31.1)
23 (59.0)
0.001
Blood Transfusion, n (%)
47 (17.0)
37 (15.6)
10 (25.6)
0.120
Unplanned return to OR, n (%)
88 (31.8)
77 (32.3)
11 (28.2)
0.606
Unplanned ICU admission, n (%)
44 (15.9)
35 (14.7)
9 (23.1)
0.185
Unplanned readmission, n (%)
17 (6.1)
16 (6.7)
1 (2.6)
0.482
Reintubation required, n (%)
21 (7.6)
18 (7.6)
3 (7.7)
0.999
Tracheostomy required, n (%)
4 (1.4)
4 (1.7)
0 (0.0)
0.999
In-hospital Mortality, n (%)
6 (2.2)
5 (2.1)
1 (2.6)
0.999
30-day Mortality, n (%)
4 (1.4)
3 (1.3)
1 (2.6)
0.457
90-day Mortality, n (%)
7 (2.5)
6 (2.5)
1 (2.6)
0.999
Median LOS (days) and range
15 (5–160)
15 (5–160)
17 (8–67)
0.301
Clavien Dindo Grade, n (%)
   
0.795
  Grade 1
9 (6.1)
7 (5.8)
2 (7.4)
 
  Grade 2
46 (31.3)
36 (30.0)
10 (37.0)
 
  Grade 3a or 3b
68 (46.3)
58 (48.4)
10 (37.0)
 
  Grade 4a or 4b
19 (12.9)
15 (12.5)
4 (14.8)
 
  Grade 5
5 (3.4)
4 (3.3)
1 (3.7)
 
LOS Length of stay
Patients over 75 were more likely to develop post-operative complications (p = 0.029), and they were more likely to be non-surgical (p = 0.001) (Table 5). Of those non-surgical complications cardiac (specifically cardiac arrythmias) and thrombo-embolic (DVT/PE) adverse events were comparatively more common (p =  < 0.001 and p = 0.017 respectively) (Appendix Table 8).
There was no difference in rates of surgical complications between age groups of oesophagectomy patients (Appendix Table 9). A conduit or anastomotic leak occurred in 39/277 patients (14.1%), 8/103 (7.8%) of whom had an Ivor Lewis versus 31/174 (17.2%) who had a 3-stage oesophagectomy (p = 0.020). Leaks in the 3-stage oesophagectomy group were predominately due to necrosis of the tip of the conduit rather than a leak from the anastomosis.
Univariable analyses are presented in Appendix Tables 10 and 11 for all complications and non-surgical complications for oesophagectomy patients. On multivariable analysis, ASA grade 3 or 4 (OR 1.85, 95% CI 1.13–3.03, p = 0.015), an operation performed in our public hospital (OR 1.78, 95% CI 1.02–3.11, p = 0.043) and a 3-stage oesophagectomy (OR 1.97, 95% CI 1.19–3.26, p = 0.009) were predictive for increased rates of all post-operative complications (surgical and non-surgical). Whilst age over 75 years, surgery performed in our public hospital and a 3-stage oesophagectomy, were predictive of non-surgical complications (Table 6 and Appendix Table 12).
Table 6
Oesophagectomy; multivariable analysis for all complications
 
Odds Ratio
95% CI
p value
ASA Grade
  
0.015
  1 or 2
Reference
  
  3 or 4
1.85
1.13–3.03
 
Hospital
  
0.043
  Private
Reference
  
  Public
1.78
1.02–3.11
 
Procedure
  
0.009
  Ivor Lewis
Reference
  
  3 Stage
1.97
1.19–3.26
 
ASA American Society of Anaesthesiologists

Gastrectomy cohort

Gastrectomy patients more likely received neoadjuvant or adjuvant systemic therapy if they were 75 years or younger (p = 0.008 and p =  < 0.001) (Table 4). Patients over 75 had a greater LOS (median 13 days vs. 12 days, p = 0.006). There was no difference in post-operative complications between age groups (Table 7). An anastomotic leak occurred in 16/189 patients (8.5%); 10/124 (8.1%) of those patients were aged 75 years or under, and 6/65 (9.2%) were over 75 (p = 0.784).
Table 7
Gastrectomy outcomes by age
 
Total population (n = 189)
Age ≤ 75 (n = 124)
Age > 75 (n = 65)
p value
Overall post-op Complications, n (%)
58(30.7)
36(29.0)
22(33.9)
0.495
Intra-op Complications, n (%)
4(2.1)
1(0.8)
3(4.6)
0.118
Surgical Complications, n (%)
32(16.9)
22(17.7)
10(15.4)
0.681
Non-Surgical Complications, n (%)
44(23.3)
25(20.2)
19(29.2)
0.161
Unplanned return to OR, n (%)
15(7.9)
9(7.3)
6(9.2)
0.634
Unplanned ICU admission, n (%)
21(11.1)
13(10.5)
8(12.3)
0.705
Unplanned admission, n (%)
13(6.9)
10(8.1)
3(4.6)
0.548
In-hospital Mortality, n (%)
2(1.1)
1(0.8)
1(1.5)
0.999
30-day Mortality, n (%)
2(1.1)
1(0.8)
1(1.5)
0.999
90-day Mortality, n (%)
3(1.6)
1(0.8)
2(3.1)
0.272
Median LOS (days) and range
12(7–232)
12(7–232)
13(8–172)
0.006
Clavien Dindo Grade, n (%)
   
0.650
  Grade 1
8(13.8)
6(16.7)
2(9.1)
 
  Grade 2
28(48.3)
15(41.7)
13(59.1)
 
  Grade 3a or 3b
11(19.0)
7(19.4)
4(18.2)
 
  Grade 4a or 4b
9(15.5)
7(19.4)
2(9.1)
 
  Grade 5
2(3.4)
1(2.8)
1(4.5)
 
LOS Length of stay
There was no difference between age groups in rates or severity of complications, and 30- and 90- day mortality. 30- and 90-day mortality rates in the older cohort were 1.5% (n = 1) and 3.1% (n = 2) and in the younger cohort 0.8% and 0.8% (n = 1) respectively (Table 7).

Discussion

The risk of complications following treatment for oesophgogastric malignancy is not insignificant and overall survival rates are low [18, 19]. The influence of the patient’s age as a predictor of complication following foregut resection would seem likely from an intuitive viewpoint. The literature regarding this however has been contradictory; some suggest advanced age is a predictor for morbidity and mortality [9, 20] while others do not corroborate this [10, 11, 21]. Surgeons should be pragmatic in their approach to the elderly patient when offering surgical resection, with particular consideration of patients’ functional baseline [22] as well as their pre-existing comorbidities. Providing accurate peri-operative mortality and complication rates to patients, allowing informed decision making, is essential. The aim of our study was therefore to scrutinise short-term outcomes in elderly patients undergoing oesophagogastric resection within our institution.
In our series, elderly patients were more likely to have a higher ASA grade and more pre-treatment comorbidities. Advanced age was a predictor for non-surgical complications in those undergoing an oesophagectomy, specifically they were more likely to develop cardiac arrythmia and thromboembolic complications. Prophylactic beta blockade has been purported to prevent atrial fibrillation following oesophagectomy, however, due to conflicting evidence for and against the use of beta blockers, our institution has not adopted this for routine practice [2325]. Despite some evidence for prolonged use of post-discharge DVT prophylaxis it has not been the policy of our treating group to mandate post-discharge DVT prophylaxis in all our resected patients. It is well recognised that patients undergoing neoadjuvant chemotherapy develop deep venous thrombosis during their treatment [26] and our results raise the question as to whether routine screening for DVT may be appropriate following neoadjuvant chemotherapy. Our data show that increased age did not confer an increased risk of complications in patients undergoing gastrectomy. At our institution, for patients undergoing oesophagogastric resection, it appears that age has not been a factor in determining post-operative mortality.
Along with higher ASA grade and type of oesophageal resection, patients undergoing oesophageal resection in our public facility had higher complication rates than patients in our private facility. Trainee surgeons performing oesophagogastric resection were supervised by the consultant surgeon authors. The surgical and anaesthetic approach and post-operative care were identical in both co-located facilities. No other factors predicting a higher risk of complication were able to be identified in this group of patients. This disparity in complication rates is the subject of ongoing evaluation in our unit.
Curative treatment of oesophagogastric malignancy is challenging for patients, carers, and health care professionals. Overall 5-year survival rates for oesophageal cancer are around 10–22% [27], and 33% for gastric cancer [28]. Identifying patients in whom rates of complication may be sufficiently high to not recommend curative treatment is critical.
The authors recognise limitations to this study, including the retrospective design. This was mitigated by prospective collection of data and therefore no recall bias, no exclusion of appropriate patients and a large study size. The study spanned 18 years with standardised surgical data collected by two surgeons throughout. During this timeframe however the treatment paradigm for these malignancies has evolved and we understand this may have impacted the peri-operative outcomes. The data are from a single institution, and future work could look to collaborate in a multi-centre approach. It has not been our practice to routinely assess patient frailty prior to offering treatment however, there is an increasing body of evidence that frailty may be a more accurate predictor of perioperative outcome than age [2931]. A number of clinical and radiological scoring systems have been developed with a view to risk stratification [3234], an example being the Edmonton Frail Scale which is a validated and practical screening tool for frailty [35]. Perhaps a specific adaptation of these methods that is applicable to geriatric patients undergoing workup for curative treatment of oesophagogastric malignancy may become clinically relevant in the future. An obvious limitation of our study is that of selection bias. All patients referred to our unit for consideration of curative resection were presented at our Multidisciplinary team meeting. Not all patients with localised disease within our referral network were discussed at our meeting. Conceivably, if an elderly patient was diagnosed with oesophageal malignancy and it was felt by the diagnosing gastroenterologist or the patient’s general practitioner that the patient was unfit for surgery, they may not have been referred for discussion. Unfortunately, it is therefore impossible to calculate a denominator of patients which includes patients over 75 with potentially curable disease who were not offered resection. While this absence of a denominator detracts from the strength of our study, we believe our conclusion that resection should be offered to selected elderly patients is valid.

Conclusion

This study shows that curative surgical resection can be offered safely to elderly patients without significant adverse outcomes, or increased peri-operative morbidity, and with acceptable post-operative mortality rates. Age alone is not a reliable predictor of poor outcomes, and therefore our unit will continue to offer surgery, including the use of adjuvant therapies, to select patients over the age of 75. Improving methods for identifying patients at greater risk of complications following oesophagogastric resection should be a priority for clinicians into the future.

Declarations

Conflict of interest

No conflicts of interest to declare.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Titel
The Impact of Age on the Post-operative Outcomes in Patients Undergoing Resection for Oesophageal and Gastric Cancer
Verfasst von
Cameron Law
Nazim Bhimani
David Mitchell
Mia Yue Yu
Priscilla Chan
Steven Leibman
Garett Smith
Publikationsdatum
18.10.2023
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 12/2023
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-023-07223-x

Appendix

See Tables
Table 8
Oesophagectomy breakdown of non-surgical complications by age
 
Total population (n = 277)
Age ≤ 75 (n = 238)
Age > 75 (n = 39)
p value
Cardiac Ischaemic event, n (%)
1 (0.4)
1 (0.4)
0 (0.0)
0.999
Cardiac Arrhythmia, n (%)
41 (14.8)
27 (11.3)
14 (35.9)
< 0.001
Other cardiovascular, n (%)
3 (1.1)
2 (0.8)
1 (2.6)
0.367
Pneumonia, n (%)
29 (10.5)
23 (9.7)
6 (15.4)
0.267
PE/DVT, n (%)
14 (5.1)
9 (3.8)
5 (12.8)
0.017
Other Pulmonary, n (%)
30 (10.8)
25 (10.5)
5 (12.8)
0.666
Renal, n (%)
2 (0.7)
2 (0.8)
0 (0.0)
0.999
CNS*, n (%)
7 (2.5)
4 (1.7)
3 (7.7)
0.060
Other non-surgical complication, n (%)
20 (7.2)
16 (6.7)
4 (10.3)
0.500
*6 patients with delirium, 1 with a seizure
PE Pulmonary embolism; DVT Deep venous thrombosis; CNS Central nervous system
8,
Table 9
Oesophageal surgical complications by age
 
Total population (n = 277)
Age ≤ 75 (n = 238)
Age > 75 (n = 39)
p value
Anastomotic Leak, n (%)
     
0.621
  Yes
39 (14.1)
35 (14.7)
4 (10.3)
 
  No
238 (85.9)
203 (85.3)
35 (89.7)
 
Wound Infection, n (%)
     
0.758
  Yes
19 (6.9)
16 (6.7)
3 (7.7)
 
  No
258 (93.1)
222 (93.3)
36 (92.3)
 
Peritonitis, n (%)
     
0.999
  Yes
1 (0.4)
1 (0.4)
0 (0.0)
 
  No
276 (99.6)
237 (99.6)
39 (100.0)
 
Chylothorax, n (%)
     
0.999
  Yes
16 (5.8)
14 (5.9)
2 (5.1)
 
  No
261 (94.2)
224 (94.1)
37 (94.9)
 
Pleural Effusion, n (%)
     
0.223
  Yes
25 (9.0)
24 (10.1)
1 (2.6)
 
  No
252 (91.0)
214 (89.9)
38 (97.4)
 
Abscess, n (%)
     
0.999
  Yes
2 (0.7)
2 (0.8)
0 (0.0)
 
  No
275 (99.3)
236 (99.2)
39 (100.0)
 
Bleeding, n (%)
     
0.999
  Yes
7 (2.5)
6 (2.5)
1 (2.6)
 
  No
270 (97.5)
232 (97.5)
38 (97.4)
 
Jejunal Tube Complication, n (%)
       
  Yes
3 (1.1)
3 (1.3)
0 (0.0)
 
  No
274 (98.9)
235 (98.7)
39 (100.0)
0.999
Other surgical complication, n (%)
     
0.999
  Yes
27 (9.8)
23 (9.7)
4 (10.3)
 
  No
250 (90.2)
215 (90.3)
35 (89.7)
 
9,
Table 10
Univariable analysis; oesophagectomy all complications
Variable
Odds ratio
95% CI
p value
Age
   
0.032
  <  = 75 years
Reference
   
  > 75 years
2.21
1.07–4.57
 
Sex
   
0.829
  Female
Reference
   
  Male
1.07
0.59–1.92
 
ASA Grade
   
0.013
  1 or 2
Reference
   
  3 or 4
1.85
1.14–3.00
 
COPD
   
0.045
  No
Reference
   
  Yes
2.23
1.02–4.87
 
HTN
   
0.871
  No
Reference
   
  Yes
1.04
0.62–1.77
 
CAD
   
0.016
  No
Reference
   
  Yes
2.42
1.18–4.96
 
Arrhythmia
   
0.045
  No
Reference
   
  Yes
2.4
1.02–5.66
 
Diabetes
   
0.581
  No
Reference
   
  Yes
1.23
0.59–2.56
 
PE/DVT
   
0.828
  No
Reference
   
  Yes
0.88
0.28–2.80
 
TIA/CVA
   
0.285
  No
Reference
   
  Yes
2.12
0.54–8.36
 
Smoking
   
0.775
  No
Reference
   
  Yes
0.88
0.35–2.18
 
Renal
   
0.17
  No
Reference
   
  Yes
4.54
0.52–39.40
 
Pre-surgery treatment
   
0.008
  Chemo-radiotherapy
Reference
   
  Chemotherapy
0.45
0.26–0.77
 
  None
1
0.53–1.88
 
Hospital Type
   
0.02
  Private
Reference
   
  Public
1.91
1.11–3.29
 
Procedure type
   
0.008
  Ivor Lewis
Reference
   
  3 Stage
1.95
1.19–3.19
 
T Stage
   
0.027
  T0
Reference
   
  T1
0.98
0.40–2.40
 
  T2
0.74
0.28–1.98
 
  T3
0.4
0.17–0.95
 
  T4
0.48
0.13–1.81
 
N Stage
   
0.096
  N0
Reference
   
  N1
0.53
0.31–0.92
 
  N2
1.32
0.55–3.18
 
  N3
0.74
0.27–2.08
 
ASA American Society of Anaesthesiologists; COPD Chronic Obstruction Pulmonary Disease; HTN Hypertension; CAD Coronary artery disease; PE Pulmonary embolism; DVT Deep venous thrombosis; TIA Transient ischaemic attack; CVA Cerebrovascular accident
10,
Table 11
Univariable analysis; oesophagectomy non-surgical complications
Variable
Odds ratio
95% CI
p value
Age
   
0.001
  <  = 75 years
Reference
   
  > 75 years
1.23
1.59–6.38
 
Sex
   
0.848
  Female
Reference
   
  Male
1.06
0.57–1.97
 
ASA grade
   
0.012
  1 or 2
Reference
   
  3 or 4
1.9
1.15–3.14
 
COPD
   
0.863
  No
Reference
   
  Yes
1.07
0.50–2.28
 
HTN
   
0.517
  No
Reference
   
  Yes
0.83
0.48–1.45
 
CAD
   
0.199
  No
Reference
   
  Yes
1.56
0.79–3.05
 
Arrhythmia
   
0.004
  No
Reference
   
  Yes
3.26
1.46–7.29
 
Diabetes
   
0.184
  No
Reference
   
  Yes
1.65
0.79–3.43
 
PE/DVT
   
0.273
  No
Reference
   
  Yes
1.91
0.60–6.10
 
TIA/CVA
   
0.106
  No
Reference
   
  Yes
2.9
0.80–10.54
 
Smoking
   
0.999
  No
Reference
   
  Yes
1
0.38–2.59
 
Renal
   
0.444
  No
Reference
   
  Yes
1.88
0.37–9.51
 
Pre-surgery treatment
   
0.033
  Chemo-radiotherapy
Reference
   
  Chemotherapy
0.49
0.27–0.89
 
  None
1.07
0.57–2.01
 
Hospital Type
   
0.009
  Private
Reference
   
  Public
2.07
1.20–3.55
 
Procedure type
   
0.009
  Ivor Lewis
Reference
   
  3 Stage
2.04
1.19–3.49
 
T Stage
   
0.01
  T0
Reference
   
  T1
0.94
0.39–2.24
 
  T2
1
0.38–2.63
 
  T3
0.45
0.19–1.07
 
  T4
0.83
0.22–3.20
 
N Stage
   
0.307
  N0
Reference
   
  N1
0.76
0.42–1.37
 
  N2
1.46
0.62–3.43
 
  N3
1.85
0.66–5.21
 
ASA American Society of Anaesthesiologists; COPD Chronic Obstruction Pulmonary Disease; HTN Hypertension; CAD Coronary artery disease; PE Pulmonary embolism; DVT Deep venous thrombosis; TIA Transient ischaemic attack; CVA Cerebrovascular accident
11,
Table 12
Oesophageal cohort multivariable analysis for non-surgical complications
 
Odds ratio
95% CI
p value
Age
   
< 0.001
  <  = 75 years
Reference
   
  > 75 years
3.70
1.79–7.64
 
Hospital type
   
0.005
  Private
Reference
   
  Public
2.24
1.27–3.94
 
Procedure type
   
0.010
  Ivor Lewis
Reference
   
  3 Stage
2.09
1.19–3.65
 
12
1.
Zurück zum Zitat Parkin DM et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
2.
Zurück zum Zitat Rawla P, Barsouk A (2018) Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019 14:26–38
3.
Zurück zum Zitat Pasquali S et al (2017) Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma. Ann Surg 265(3):481–491CrossRefPubMed
4.
Zurück zum Zitat Biondi A et al (2015) Neo-adjuvant chemo(radio)therapy in gastric cancer: current status and future perspectives. World J Gastrointest Oncol 7(12):389–400CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Shapiro J et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098CrossRefPubMed
6.
Zurück zum Zitat Seymour DG, Pringle R (1983) Post-operative complications in the elderly surgical patient. Gerontology 29(4):262–270CrossRefPubMed
7.
Zurück zum Zitat Yamada H et al (2013) Postoperative complications in the oldest old gastric cancer patients. Int J Surg 11(6):467–471CrossRefPubMed
8.
Zurück zum Zitat Lee K-G et al (2014) Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien-Dindo system. J Gastrointest Surg 18(7):1269–1277CrossRefPubMed
9.
Zurück zum Zitat Klevebro F et al (2019) Surgical outcomes of oesophagectomy or gastrectomy due to cancer for patients≥ 75 years of age: a single-centre cohort study. ANZ J Surg 89(3):228–233CrossRefPubMed
10.
Zurück zum Zitat Wu C-W et al (2000) Surgical mortality, survival, and quality of life after resection for gastric cancer in the elderly. World J Surg 24(4):465–472CrossRefPubMed
11.
Zurück zum Zitat Jeong O et al (2010) Effect of age on surgical outcomes of extended gastrectomy with D2 lymph node dissection in gastric carcinoma: prospective cohort study. Ann Surg Oncol 17(6):1589–1596CrossRefPubMed
12.
Zurück zum Zitat Ruol A et al (2007) Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol 14(11):3243–3250CrossRefPubMed
13.
Zurück zum Zitat Fogh SE et al (2011) Do elderly patients experience increased perioperative or postoperative morbidity or mortality when given neoadjuvant chemoradiation before esophagectomy? Int J Radiat Oncol Biol Phys 80(5):1372–1376CrossRefPubMed
14.
Zurück zum Zitat Lorenzen S et al (2013) Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Br J Cancer 108(3):519–526CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Dripps R (1963) New classification of physical status. Anesthesiology 24:111
16.
Zurück zum Zitat Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Low DE et al (2015) International consensus on standardization of data collection for complications associated with esophagectomy. Ann Surg 262(2):286–294CrossRefPubMed
18.
Zurück zum Zitat Sihvo EI, Luostarinen ME, Salo JA (2004) Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Off J Am College Gastroenterol ACG 99(3):419–424CrossRef
19.
Zurück zum Zitat Bailey SH et al (2003) Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 75(1):217–222CrossRefPubMed
20.
Zurück zum Zitat Zhou C-J et al (2016) Feasibility of radical gastrectomy for elderly patients with gastric cancer. Eur J Surg Oncol (EJSO) 42(2):303–311CrossRefPubMed
21.
Zurück zum Zitat Paulus E et al (2017) Esophagectomy for cancer in octogenarians: should we do it? Langenbecks Arch Surg 402(3):539–545CrossRefPubMed
22.
Zurück zum Zitat Lidoriki I et al (2022) The impact of nutritional and functional status on postoperative outcomes following esophageal cancer Surgery. Nutr Cancer 74(8):2846–2858CrossRefPubMed
23.
Zurück zum Zitat Dunkelgrun M et al (2009) Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 249(6):921–926CrossRefPubMed
24.
Zurück zum Zitat Bouri S et al (2014) Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart 100(6):456–464CrossRefPubMed
25.
Zurück zum Zitat Wijeysundera DN et al (2014) Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 130(24):2246–2264CrossRefPubMed
26.
Zurück zum Zitat Di Nisio M et al (2018) Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost 16(7):1336–1346CrossRefPubMed
27.
Zurück zum Zitat Huang F-L, Yu S-J (2018) Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg 41(3):210–215CrossRefPubMed
28.
Zurück zum Zitat AioHa W (2021) Cancer data in Australia. AIHW, Australia
29.
Zurück zum Zitat Tegels JJ et al (2014) Value of geriatric frailty and nutritional status assessment in predicting postoperative mortality in gastric cancer surgery. J Gastrointest Surg 18(3):439–446CrossRefPubMed
30.
Zurück zum Zitat Makary MA et al (2010) Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 210(6):901–908CrossRefPubMed
31.
Zurück zum Zitat Hewitt J et al (2015) Prevalence of frailty and its association with mortality in general surgery. Am J Surg 209(2):254–259CrossRefPubMed
32.
Zurück zum Zitat Wallis S et al (2015) Association of the clinical frailty scale with hospital outcomes. QJM Int J Med 108(12):943–949CrossRef
33.
Zurück zum Zitat Bentov I et al (2019) Frailty assessment: from clinical to radiological tools. Br J Anaesth 123(1):37–50CrossRefPubMed
34.
Zurück zum Zitat Rockwood K et al (2005) A global clinical measure of fitness and frailty in elderly people. CMAJ 173(5):489–495CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Rolfson DB et al (2006) Validity and reliability of the Edmonton Frail Scale. Age Ageing 35(5):526–529CrossRefPubMedPubMedCentral

Neu im Fachgebiet Chirurgie

Opportunistische Salpingektomie lohnt sich häufig

Eine opportunistische Eileiterentfernung reduziert das Risiko für tubo-ovarielle Karzinome um 40 bis 80% – ohne kurzfristige Nachteile für die Ovarialfunktion. Die Europäische Gynäkologievereinigung rät Frauen ohne Kinderwunsch daher, solche Eingriffe zu nutzen.

Kopfverband nach Mittelohr-OP: Braucht es das wirklich?

Nach einer Mittelohr-OP ist ein Druckverband um den Kopf, wie er in vielen HNO-Kliniken routinemäßig angelegt wird, wohl überflüssig. Laut einem Team aus Pakistan ist der Schaden, der damit angerichtet wird, wahrscheinlich größer als der Nutzen.

Video

S2k-Leitlinie Rotatorenmanschettenruptur

Rupturen der Rotatorenmanschette zählen zu den häufigsten Schultererkrankungen. Je nach Alter sind die Ursachen unterschiedlich. Welche Empfehlungen die neue S2k-Leitlinie für Diagnostik, OP-Indikation und Therapie gibt, erklärt Prof. Dennis Liem im Interviewformat MedTalk Leitlinie KOMPAKT der Zeitschrift Orthopädie und Unfallchirurgie.

MedTalk Leitlinie KOMPAKT

Aorteninsuffizienz: „Grenzwerte bei Frauen senken!“

Frauen mit schwerer Aortenklappenregurgitation erhalten die rettende Klappen-Op. möglicherweise oft zu spät. Auf der Basis einer Multicenterstudie fordert ein internationales Team volumetrische linksventrikuläre Messungen und geschlechtsspezifische Grenzwerte, um das Risiko besser einzuschätzen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Bildnachweise
Hysterektomie/© nkeskin / Getty Images / iStock, Arzt untersucht Patient an der Schulter/© contrastwerkstatt / Stock.adobe.com (Symbolbild mit Fotomodellen)